Symbols / ADIL $1.96 +4.81%
ADIL Chart
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.80M |
| Enterprise Value | -3.08M | Income | -7.98M | Sales | — |
| Book/sh | 4.75 | Cash/sh | 4.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -0.40 | PEG | — |
| P/S | — | P/B | 0.41 | P/C | — |
| EV/EBITDA | 0.40 | EV/Sales | — | Quick Ratio | 4.21 |
| Current Ratio | 4.42 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -11.93 | EPS next Y | -4.84 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 17:00 | ROA | -83.20% |
| ROE | -170.73% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.43M |
| Shs Float | 1.31M | Short Float | 2.52% | Short Ratio | 0.47 |
| Short Interest | — | 52W High | 30.25 | 52W Low | 1.54 |
| Beta | 1.32 | Avg Volume | 71.69K | Volume | 31.39K |
| Target Price | $23.33 | Recom | Strong_buy | Prev Close | $1.87 |
| Price | $1.96 | Change | 4.81% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.33
Mean price target
2. Current target
$1.96
Latest analyst target
3. DCF / Fair value
$-47.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.96
Low
$8.00
High
$42.00
Mean
$23.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | up | Maxim Group | Hold → Buy | $2 |
| 2024-11-14 | init | Rodman & Renshaw | — → Buy | $8 |
- FDA policy shift could give Adial cheaper route for alcohol-use drug - Stock Titan Fri, 06 Mar 2026 13
- Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why - Yahoo Finance hu, 10 Jul 2025 07
- Maxim Group Upgrades Adial Pharmaceuticals (ADIL) - Nasdaq ue, 30 Sep 2025 07
- Genetic alcohol use drug AD04 lines up $60M Europe framework - Stock Titan ue, 03 Mar 2026 08
- Why Is Adial Pharmaceuticals Stock (ADIL) Down Today? - TipRanks hu, 05 Feb 2026 08
- Adial Pharmaceuticals Receives 180-Day Extension to Regain Nasdaq Compliance with Minimum Bid Price Requirement - Quiver Quantitative Wed, 03 Sep 2025 07
- Adial Pharmaceuticals stock tumbles after announcing 1-for-25 reverse split - Investing.com ue, 03 Feb 2026 08
- Market Movers | Winners: ASST, ADIL, RLYB | Losers: EAF, ERNA, ANEB - Trefis Fri, 06 Feb 2026 08
- All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy - Yahoo Finance Mon, 01 Sep 2025 07
- Adial (NASDAQ: ADIL) outlines 2026 cash runway and FDA End of Phase 2 guidance for lead drug - Stock Titan Fri, 14 Nov 2025 08
- Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks ue, 03 Mar 2026 13
- Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa Mon, 23 Feb 2026 19
- Market Movers | Winners: ADIL, ASST, RLYB | Losers: OBAI, GEOS, PFSA - Trefis hu, 05 Feb 2026 08
- New FDA trial policy could speed addiction drug for heavy drinkers - Stock Titan Mon, 23 Feb 2026 08
- Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - TipRanks ue, 24 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.80M | -3.82M | -6.89M | -10.86M |
| TotalUnusualItems | 0.00 | -4.46M | 0.00 | 522.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -4.46M | 0.00 | 522.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.98M | -13.20M | -7.00M | -10.80M |
| ReconciledDepreciation | 565.00 | 565.00 | 564.00 | 564.00 |
| EBITDA | -7.80M | -8.28M | -6.89M | -10.86M |
| EBIT | -7.80M | -8.28M | -6.89M | -10.86M |
| NetInterestIncome | 149.57K | 178.66K | 69.78K | 63.34K |
| InterestIncome | 149.57K | 178.66K | 69.78K | 63.34K |
| NormalizedIncome | -7.98M | -8.73M | -7.00M | -10.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.98M | -13.20M | -5.12M | -12.73M |
| TotalExpenses | 7.80M | 8.28M | 6.89M | 10.86M |
| TotalOperatingIncomeAsReported | -7.80M | -8.28M | -6.89M | -10.86M |
| DilutedAverageShares | 194.06K | 56.99K | 40.06K | 29.74K |
| BasicAverageShares | 194.06K | 56.99K | 40.06K | 29.74K |
| DilutedEPS | -68.01 | -90.00 | -317.75 | -650.00 |
| BasicEPS | -68.01 | -90.00 | -317.75 | -650.00 |
| DilutedNIAvailtoComStockholders | -7.98M | -13.20M | -5.12M | -12.73M |
| NetIncomeCommonStockholders | -7.98M | -13.20M | -5.12M | -12.73M |
| NetIncome | -7.98M | -13.20M | -5.12M | -12.73M |
| NetIncomeIncludingNoncontrollingInterests | -7.98M | -13.20M | -5.12M | -12.73M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.88M | -1.94M | |
| NetIncomeContinuousOperations | -7.98M | -13.20M | -7.00M | -10.80M |
| TaxProvision | 0.00 | 0.00 | 0.00 | -94.08K |
| PretaxIncome | -7.98M | -13.20M | -7.00M | -10.80M |
| OtherIncomeExpense | -327.28K | -5.09M | -183.72K | 522.00K |
| OtherNonOperatingIncomeExpenses | 164.85K | -75.04K | 10.16K | 46.49K |
| SpecialIncomeCharges | 0.00 | -4.46M | 0.00 | 522.00K |
| OtherSpecialCharges | 4.46M | |||
| WriteOff | 0.00 | 1.55M | ||
| ImpairmentOfCapitalAssets | 1.55M | |||
| RestructuringAndMergernAcquisition | -522.00K | 281.71K | ||
| EarningsFromEquityInterest | -492.13K | -552.18K | -193.88K | 0.00 |
| NetNonOperatingInterestIncomeExpense | 149.57K | 178.66K | 69.78K | 63.34K |
| InterestIncomeNonOperating | 149.57K | 178.66K | 69.78K | 63.34K |
| OperatingIncome | -7.80M | -8.28M | -6.89M | -10.86M |
| OperatingExpense | 7.80M | 8.28M | 6.89M | 10.86M |
| ResearchAndDevelopment | 2.62M | 3.23M | 1.27M | 1.95M |
| SellingGeneralAndAdministration | 5.18M | 5.06M | 5.62M | 8.91M |
| GeneralAndAdministrativeExpense | 5.18M | 5.06M | 5.62M | 8.91M |
| OtherGandA | 5.18M | 5.06M | 5.62M | 8.91M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.11M | 258.98K | 66.54K | 42.70K |
| ShareIssued | 1.11M | 258.98K | 66.54K | 42.70K |
| TotalDebt | 207.38K | 256.96K | ||
| TangibleBookValue | 5.27M | 4.06M | 4.08M | 3.27M |
| InvestedCapital | 5.28M | 4.07M | 4.08M | 3.28M |
| WorkingCapital | 4.78M | 3.08M | 2.55M | 2.99M |
| NetTangibleAssets | 5.27M | 4.06M | 4.08M | 3.27M |
| CapitalLeaseObligations | 207.38K | 256.96K | ||
| CommonStockEquity | 5.28M | 4.07M | 4.08M | 3.28M |
| TotalCapitalization | 5.28M | 4.07M | 4.08M | 3.28M |
| TotalEquityGrossMinorityInterest | 5.28M | 4.07M | 4.08M | 3.28M |
| StockholdersEquity | 5.28M | 4.07M | 4.08M | 3.28M |
| RetainedEarnings | -89.97M | -82.00M | -68.80M | -63.67M |
| AdditionalPaidInCapital | 95.25M | 86.06M | 72.88M | 66.95M |
| CapitalStock | 1.11K | 259.00 | 1.66K | 1.07K |
| CommonStock | 1.11K | 259.00 | 1.66K | 1.07K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.40M | 975.86K | 653.08K | 2.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 665.44K |
| OtherNonCurrentLiabilities | 492.00K | 1.01M | ||
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 665.44K | ||
| NonCurrentDeferredLiabilities | 22.90K | 23.40K | ||
| NonCurrentDeferredTaxesLiabilities | 22.90K | 23.40K | ||
| LongTermDebtAndCapitalLeaseObligation | 150.55K | 207.38K | ||
| LongTermCapitalLeaseObligation | 150.55K | 207.38K | ||
| CurrentLiabilities | 1.40M | 975.86K | 653.08K | 1.79M |
| OtherCurrentLiabilities | 376.13K | 9.68K | ||
| CurrentDebtAndCapitalLeaseObligation | 56.83K | 49.59K | ||
| CurrentCapitalLeaseObligation | 56.83K | 49.59K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 660.31K | 405.25K | 421.37K | 761.51K |
| PayablesAndAccruedExpenses | 736.60K | 570.61K | 231.71K | 653.23K |
| CurrentAccruedExpenses | 81.39K | 272.21K | 104.32K | 376.82K |
| Payables | 655.21K | 298.40K | 127.39K | 276.41K |
| DuetoRelatedPartiesCurrent | 0.00 | 48.27K | 24.06K | 0.00 |
| AccountsPayable | 655.21K | 250.13K | 103.33K | 276.41K |
| TotalAssets | 6.67M | 5.04M | 4.74M | 5.73M |
| TotalNonCurrentAssets | 492.48K | 985.18K | 1.54M | 952.87K |
| OtherNonCurrentAssets | 948.39K | |||
| NonCurrentPrepaidAssets | 0.00 | |||
| InvestmentsAndAdvances | 489.70K | 981.83K | 1.53M | 0.00 |
| LongTermEquityInvestment | 489.70K | 981.83K | 1.53M | 0.00 |
| GoodwillAndOtherIntangibleAssets | 2.78K | 3.35K | 3.91K | 4.48K |
| OtherIntangibleAssets | 3.91K | 4.48K | 460.04K | |
| Goodwill | 248.97K | 248.97K | ||
| NetPPE | 244.42K | 304.36K | ||
| GrossPPE | 244.42K | 304.36K | ||
| OtherProperties | 50.42K | 58.15K | ||
| BuildingsAndImprovements | 194.00K | 246.21K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 6.18M | 4.06M | 3.20M | 4.78M |
| OtherCurrentAssets | 299.67K | 308.24K | 371.60K | 349.44K |
| AssetsHeldForSaleCurrent | 0.00 | 428.70K | ||
| PrepaidAssets | 428.70K | 9.93K | ||
| CashCashEquivalentsAndShortTermInvestments | 5.88M | 3.75M | 2.83M | 4.00M |
| CashAndCashEquivalents | 5.88M | 3.75M | 2.83M | 4.00M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.49M | -6.92M | -6.81M | -11.19M |
| IssuanceOfCapitalStock | 3.66M | 4.02M | 749.94K | 9.12M |
| CapitalExpenditure | -64.61K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 5.88M | 3.75M | 2.83M | 4.00M |
| BeginningCashPosition | 3.75M | 2.83M | 4.00M | 6.06M |
| ChangesInCash | 2.13M | 923.44K | -1.17M | -2.06M |
| FinancingCashFlow | 8.47M | 7.85M | 4.13M | 9.13M |
| CashFlowFromContinuingFinancingActivities | 8.47M | 7.85M | 4.13M | 9.13M |
| NetOtherFinancingCharges | -1.66K | |||
| ProceedsFromStockOptionExercised | 4.81M | 3.82M | 3.38M | 1.86K |
| NetCommonStockIssuance | 3.66M | 4.02M | 749.94K | 9.12M |
| CommonStockIssuance | 3.66M | 4.02M | 749.94K | 9.12M |
| InvestingCashFlow | 150.00K | 0.00 | 1.50M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 150.00K | 0.00 | 1.50M | 0.00 |
| NetOtherInvestingChanges | 1.50M | |||
| NetBusinessPurchaseAndSale | 150.00K | 0.00 | 0.00 | 30.59K |
| SaleOfBusiness | 150.00K | 0.00 | 0.00 | 30.59K |
| NetPPEPurchaseAndSale | 0.00 | -64.61K | ||
| PurchaseOfPPE | 0.00 | -64.61K | ||
| OperatingCashFlow | -6.49M | -6.92M | -6.81M | -11.19M |
| CashFromDiscontinuedOperatingActivities | -1.00M | -2.59M | ||
| CashFlowFromContinuingOperatingActivities | -6.49M | -6.92M | -5.80M | -8.59M |
| ChangeInWorkingCapital | 465.67K | 386.14K | -794.21K | -1.17M |
| ChangeInOtherCurrentLiabilities | -49.59K | -37.34K | ||
| ChangeInPayablesAndAccruedExpense | 457.10K | 322.78K | -772.05K | -1.22M |
| ChangeInAccruedExpense | 100.30K | 151.77K | -612.64K | -1.24M |
| ChangeInPayable | 356.81K | 171.01K | -159.41K | 15.83K |
| ChangeInAccountPayable | 356.81K | 171.01K | -159.41K | 15.83K |
| ChangeInPrepaidAssets | 8.57K | 63.36K | -22.16K | 49.99K |
| OtherNonCashItems | -150.00K | 4.54M | 51.90K | -522.00K |
| StockBasedCompensation | 676.20K | 796.83K | 1.75M | 3.37M |
| AssetImpairmentCharge | 0.00 | 1.55M | ||
| DeferredTax | -502.00 | -94.08K | ||
| DeferredIncomeTax | -502.00 | -94.08K | ||
| DepreciationAmortizationDepletion | 565.00 | 565.00 | 564.00 | 564.00 |
| DepreciationAndAmortization | 565.00 | 565.00 | 564.00 | 564.00 |
| AmortizationCashFlow | 565.00 | 565.00 | 564.00 | 564.00 |
| AmortizationOfIntangibles | 565.00 | 565.00 | 564.00 | 564.00 |
| Depreciation | 59.94K | 54.54K | ||
| OperatingGainsLosses | 492.13K | 552.18K | 193.88K | -22.13K |
| EarningsLossesFromEquityInvestments | 492.13K | 552.18K | 193.88K | 0.00 |
| GainLossOnSaleOfPPE | 0.00 | 6.95K | ||
| NetIncomeFromContinuingOperations | -7.98M | -13.20M | -7.00M | -10.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ADIL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|